Summary of Key Information:
Reporting Period (Quarter/Year): Financial Year ended March 31, 2026
Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI Listing Regulations
Audit Opinion:
Not Specified
Key Financial Highlights:
Standalone Results: Not Specified
Consolidated Results: Not Specified
Segment-wise Performance:
Not Specified
Corporate Actions:
- Dividend: Not declared
- Share Capital Increase: Approved increase in authorized share capital from ₹1,100,000,000 (Rupees One Hundred and Ten Crore Only) to ₹1,300,000,000 (Rupees One Hundred and Thirty Crore Only)
- Preferential Issue: Approved issuance of 8,58,83,617 Equity Shares of face value ₹2 each at price of ₹17.85 per share (including security premium of ₹15.85 per share) for consideration other than cash
- Share Swap Acquisitions:
- Acquisition of up to 44.94% shareholding in Apiqo Organics Private Limited (45,16,200 equity shares) for ₹1,165,179,600
- Acquisition of up to 47.41% shareholding in Bizotic Lifescience Private Limited (22,99,000 equity shares) for ₹367,840,000
Other Significant Information:
- Annual General Meeting: Scheduled for Saturday, September 5, 2026 at 11:00 A.M. IST through Video Conferencing / Other Audio Visual Means
- Register Closure: Register of Members and Share Transfer Books to remain closed from August 29, 2026 to September 4, 2026 (both days inclusive)
- E-voting: Period commences on September 2, 2026 (9:00 A.M. IST) and ends on September 4, 2026 (5:00 P.M. IST)
- Scrutinizer Appointment: M/s. K.P. Ghelani & Associates, Company Secretaries appointed as Scrutinizer for e-voting process
- Acquisition Details:
- Apiqo Organics: Share exchange ratio 1:14.45, consideration ₹258 per share
- Bizotic Lifescience: Share exchange ratio 1:8.96, consideration ₹160 per share
- Both acquisitions subject to shareholder acceptance and regulatory approvals